What’s the current market cap for GeneDx Holdings stock?

GeneDx Holdings (WGS) has a market cap of $1.5B as of May 27, 2026.

What is the P/E ratio for GeneDx Holdings stock?

The price to earnings (P/E) ratio for GeneDx Holdings (WGS) stock is 0 as of May 27, 2026.

Does GeneDx Holdings stock pay dividends?

No, GeneDx Holdings (WGS) stock does not pay dividends to its shareholders as of May 27, 2026.

When is the next GeneDx Holdings dividend payment date?

GeneDx Holdings (WGS) stock does not pay dividends to its shareholders.

What is the beta indicator for GeneDx Holdings?

GeneDx Holdings (WGS) has a beta rating of 2.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy GeneDx Holdings stock | $WGS Share Price

13:30

09:10

04:45

00:25

20:00

About GeneDx Holdings

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Ticker

$WGS

Sector

Health

Primary listing

NASDAQ

Employees

1,300

Headquarters

Stamford, United States

Website

www.genedx.com

GeneDx Holdings Metrics

BasicAdvanced

$1.5bn

-$2.69

2.07

Bulls say / Bears say

Delivered fourth-quarter 2025 revenue of $121.0 million and full-year 2025 revenue of $427.5 million, meeting guidance and reflecting continued momentum in core exome and genome sequencing services.

Achieved full-year exome and genome revenue growth of 54% (58% excluding a one-time benefit) and fourth-quarter volume growth of 34.3% year-over-year to 27,761 tests, underscoring robust market adoption.

Issued 2026 guidance projecting $540 million–$555 million in revenue and 33%–35% exome and genome volume growth, indicating confidence in a sustained high-growth trajectory.

Reported Q1 2026 revenue of $102.3 million, missing the $112.45 million consensus and EPS of -$0.28 versus -$0.01 estimate, triggering a 46.4% share decline.

Slashed full-year 2026 revenue guidance by 12% to $475 million–$490 million from $540 million–$555 million, with a midpoint of $482.5 million well below analysts’ $550 million forecast, reflecting execution and mix headwinds.

Recorded an adjusted net loss of $8.2 million in Q1 2026 compared to adjusted net income of $9.2 million year-ago, highlighting challenges in profitability and cost control.

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $WGS

Capital at risk

Market closed

Upcoming events

No upcoming events